Internal Medicine, Pulmonary Disease · Saint Louis, MO
NPI
1407872724
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4921 Parkview Pl, Div Im Pulmonary and Ccm, 8th Fl
Saint Louis, MO, 63110
Phone (314) 454-8917
Groups this clinician bills Medicare through
Medicare paid, 2024
$101K
2,264 services
Medicare patients, 2024
769
Average age 68
Drug cost, 2024
$32.5M
6,507 prescriptions
Company payments, 2025
$40K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Murali M Chakinala was code 94010 (pulmonary function testing), 423 times for 377 patients. In total Murali M Chakinala billed 2,264 services in 37 codes, and Medicare paid $101K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94010 Pulmonary Function Testing | Office | 423 | 377 | $17.63 | $7,457 |
| 99214 Office E&M - Established | Office | 264 | 155 | $91.82 | $24K |
| 94618 Pulmonary Function Testing | Office | 247 | 235 | $22.65 | $5,593 |
| 99232 Hospital E&M - Subsequent | Facility | 182 | 68 | $59.58 | $11K |
| 94729 Pulmonary Function Testing | Office | 171 | 168 | $33.94 | $5,805 |
| 94726 Pulmonary Function Testing | Office | 150 | 148 | $35.33 | $5,300 |
| 94060 Pulmonary Function Testing | Office | 117 | 116 | $24.71 | $2,891 |
| 99233 Hospital E&M - Subsequent | Facility | 99 | 36 | $90.61 | $8,971 |
| 36600 General Laboratory | Office | 94 | 94 | $19.43 | $1,826 |
| 82375 Clinical Chemistry | Office | 92 | 92 | $11.94 | $1,098 |
| 82805 Clinical Chemistry | Office | 49 | 49 | $77.19 | $3,782 |
| 82803 Clinical Chemistry | Office | 46 | 46 | $24.99 | $1,150 |
| 99213 Office E&M - Established | Office | 35 | 31 | $59.64 | $2,087 |
| 99223 Hospital E&M - Initial | Facility | 26 | 25 | $127.31 | $3,310 |
| 99215 Office E&M - Established | Office | 22 | 22 | $138.40 | $3,045 |
By year: 2022 $94K for 2,174 services; 2023 $99K for 2,556 services; 2024 $101K for 2,264 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36600 General Laboratory | 94 | 94 | $19.43 | $1,826 |
| 82375 Clinical Chemistry | 92 | 92 | $11.94 | $1,098 |
| 82805 Clinical Chemistry | 49 | 49 | $77.19 | $3,782 |
| 82803 Clinical Chemistry | 46 | 46 | $24.99 | $1,150 |
Medicare prescription drug claims, 2024
In 2024, the drug Murali M Chakinala prescribed most often to Medicare patients was Opsumit (Macitentan), with 829 prescriptions and refills. In total Murali M Chakinala wrote 6,507 Medicare prescriptions that cost $32.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opsumit Macitentan | 829 | 829 | 90 | $10.5M |
| Tadalafil Generic | 594 | 664 | 68 | $481K |
| Spironolactone Generic | 490 | 943 | 112 | $3,688 |
| Ambrisentan Generic | 485 | 485 | 50 | $1.5M |
| Adempas Riociguat | 422 | 422 | 45 | $5.9M |
| Furosemide Generic | 382 | 748 | 95 | $1,922 |
| Sildenafil Citrate Generic | 340 | 530 | 64 | $92K |
| Potassium Chloride Generic | 242 | 481 | 61 | $7,267 |
| Bumetanide Generic | 189 | 377 | 47 | $8,097 |
| Orenitram Er Treprostinil Diolamine | 165 | 165 | Under 11 | $2.8M |
| Tyvaso Dpi Treprostinil | 155 | 155 | 13 | $3.9M |
| Jardiance Empagliflozin | 133 | 166 | 24 | $99K |
| Winrevair Sotatercept-Csrk | 126 | 126 | 17 | $2.1M |
| Uptravi Selexipag | 117 | 117 | 15 | $2.8M |
| Gabapentin Generic | 106 | 174 | 19 | $3,745 |
Brand drugs: - claims; generic drugs: 3,798 claims; opioid claims: 52.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Murali M Chakinala $40K ($40K in general payments such as food, travel and fees) from 11 companies. The largest payer was Merck Sharp & Dohme LLC with $13K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 26 | $13K |
| United Therapeutics Corporation UTHR | 18 | $11K |
| Chiesi USA, Inc. | 6 | $5,475 |
| Insmed, Inc. INSM | 3 | $4,861 |
| Actelion Pharmaceuticals US, Inc. JNJ | 4 | $3,834 |
| Alnylam Pharmaceuticals Inc. ALNY | 9 | $1,628 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $147 |
| Liquidia Technologies, Inc. | 1 | $140 |
| Penumbra, Inc. PEN | 1 | $136 |
| Sandoz Inc. SDZ.SW | 4 | $96.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.